Skip to main content
. 2021 Oct 22;374(6566):eabj9853. doi: 10.1126/science.abj9853

Fig. 4. Spike-specific antibody and T cell responses induced by mRNA-1273 vaccination.

Fig. 4.

(A to H) Immune responses to 25-μg mRNA-1273 vaccination in three adult age groups: 18–55 (light blue symbols), 56–70 (dark blue), and over 70 years of age (black). [(A) to (C)] Anti-spike IgG, anti-RBD IgG, and PSV neutralizing titers. [(D) and (E)] Spike-specific CD4+ T cells by AIM (D) or ICS (E). (F) Spike-specific cTFH cells. [(G) and (H)] Spike-specific CD8+ T cells by AIM (G) or ICS (H). Data were analyzed for statistical significance using nonparametric analysis of variance Kruskal-Wallis (KW) test and Dunn’s post-test for multiple comparisons. The P values plotted on the bottom show the KW test results, and the P values plotted on the top show the post-test analysis comparing age groups. (I) Anti-SARS-CoV-2 spike IgG, RBD IgG, and PSV neutralizing titers in 25-μg and 100-μg mRNA-1273 vaccinees at day 43 (2 weeks after second dose). (J) Spike-specific CD4+ AIM+ (left) and cytokine+ (right) T cells in mRNA-1273 vaccinees. (K) Spike-specific CD8+ AIM+ (left) and cytokine+ (right) T cells in mRNA-1273 vaccinees. Dotted green lines indicate the limit of quantification (LOQ). The bars indicate geometric mean and geomean SD. Data in (I) to (K) were analyzed for statistical significance using Mann-Whitney U test. Background-subtracted and log data analyzed in all cases.